Immunoblotting suggested that MeCP2 was mainly expressed in breast cancer cells of the luminal epithelial subtype, and E‐cadherin expression was increased in T‐47D and MCF‐7 cell lines (Figure 1A and B). Here, MECP2 is linked to breast carcinoma.